<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:video="http://www.google.com/schemas/sitemap-video/1.1"><url>
        <loc>https://www.cancernetwork.com/view/implementing-patient-education-and-supportive-care-in-egfr-mutated-metastatic-non-small-cell-lung-cancer</loc><video:video><video:publication_date>2026-04-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d0dca9d03ca4cc3748d1895713aba71b957f1366-850x476.png</video:thumbnail_loc><video:title><![CDATA[Implementing Patient Education and Supportive Care in EGFR Mutated Metastatic Non-Small Cell Lung Cancer ]]></video:title><video:description><![CDATA[In this segment, the panel discusses how complex treatment education is operationalized in routine practice for patients with EGFR mutated metastatic non-small cell lung cancer. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390393781112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/subcutaneous-amivantamab-lazertinib-a-new-soc-in-egfr-nsclc-</loc><video:video><video:publication_date>2026-04-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d98d3df5db87549f0168c488bda17c635bd8cd46-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Subcutaneous Amivantamab/Lazertinib: a New SOC in EGFR+ NSCLC?]]></video:title><video:description><![CDATA[Continuing to implement prophylactic measures is necessary to maintain the benefit of subcutaneous amivantamab plus lazertinib in this NSCLC population.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6392461208112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/access-adherence-and-dosing-flexibility-in-egfr-mutated-metastatic-non-small-cell-lung-cancer</loc><video:video><video:publication_date>2026-04-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d0dca9d03ca4cc3748d1895713aba71b957f1366-850x476.png</video:thumbnail_loc><video:title><![CDATA[Access, Adherence, and Dosing Flexibility in EGFR Mutated Metastatic Non-Small Cell Lung Cancer]]></video:title><video:description><![CDATA[In this segment, Dr. Devarakonda asks Dr. Rous to explore how treatment schedules and dosing flexibility influence shared decision making and long term adherence in EGFR mutated metastatic non-small cell lung cancer. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390392892112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/optimizing-oxybutynin-doses-for-adt-induced-hot-flashes-in-prostate-cancer</loc><video:video><video:publication_date>2026-04-02</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7ecdf09205fadbb8b00f33aed2770dd8924122fe-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Optimizing Oxybutynin Doses for ADT-Induced Hot Flashes in Prostate Cancer]]></video:title><video:description><![CDATA[Bradley J. Stish, MD, emphasized the role of decision-making processes between physicians and patients when deciding between 2.5 and 5 mg of oxybutynin.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6392360921112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/discussing-a-phase-2-defactinib-avutometinib-trial-in-diffuse-gastric-cancer</loc><video:video><video:publication_date>2026-04-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0dd830e71ae577e96ef8c138f61c89c689299b54-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Discussing a Phase 2 Defactinib/Avutometinib Trial in Diffuse Gastric Cancer]]></video:title><video:description><![CDATA[Ryan H. Moy, MD, PhD, is the principal investigator of a phase 2 trial evaluating defactinib plus avutometinib in patients with diffuse gastric/GEJ carcinoma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6392357713112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/osimertinib-across-stages-shaping-early-stage-egfr-mutated-nsclc-care</loc><video:video><video:publication_date>2026-04-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9e600743c27804eed73368187e7a4eac4f4d9211-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Osimertinib Across Stages: Shaping Early-Stage EGFR-Mutated NSCLC Care]]></video:title><video:description><![CDATA[In this segment, Dr. Alexander Spira and Dr. Edward Kim discuss how the clinical development of osimertinib across multiple disease stages has influenced treatment expectations in early-stage EGFR-mutated non–small cell lung cancer (NSCLC).]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391554870112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/debate-round-1-should-car-t-be-given-inpatient-or-outpatient</loc><video:video><video:publication_date>2026-04-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/8cc39f59a281a15f46324cb54550846f2cb771e6-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Debate Round 1: Should CAR-T Be Given Inpatient or Outpatient? ]]></video:title><video:description><![CDATA[Panelists engage in a structured debate on whether CAR T-cell therapy for aggressive large B-cell lymphoma should be administered in the inpatient or outpatient setting. Team NYC argues for inpatient treatment in higher-risk or socially complex cases, citing logistical barriers, caregiver limitations, and the need to manage serious toxicities such as CRS and ICANS. Team Roswell counters that outpatient programs can safely expand access, reduce hospital-related complications, and improve patient acceptance of CAR T, prompting a broader discussion on evolving safety data, real-world logistics, and changing regulatory requirements.
]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390643482112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/egfr-biology-and-treatment-selection-beyond-pd-l1-in-egfr-mutated-nsclc</loc><video:video><video:publication_date>2026-04-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9e600743c27804eed73368187e7a4eac4f4d9211-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[EGFR Biology and Treatment Selection Beyond PD-L1 in EGFR-Mutated NSCLC]]></video:title><video:description><![CDATA[In this segment, Alexander Spira, MD, PhD, engages Natalie Vokes, MD, in a discussion on the distinct biology of EGFR-mutated non–small cell lung cancer and how it informs treatment decisions in the early-stage setting.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391555169112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/unmet-needs-in-early-relapse-multiple-myeloma</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1037680179dd22031bb6c3ea404d1118f74f5c6e-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Unmet Needs in Early Relapse Multiple Myeloma ]]></video:title><video:description><![CDATA[]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391843169112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/how-rapid-therapeutic-evolution-has-complicated-rcc-sequencing</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b7614e52fff7bdd6f4493c629c62e21f57b92a0c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[How Rapid Therapeutic Evolution Has Complicated RCC Sequencing]]></video:title><video:description><![CDATA[]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6392173463112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/frontline-regimen-selection-in-advanced-renal-cell-carcinoma</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1a6d64ac5992ae4d126fd67e1a074defa42ab2d1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Frontline Regimen Selection in Advanced Renal Cell Carcinoma ]]></video:title><video:description><![CDATA[In this segment on advanced renal cell carcinoma, Dr. Ornstein guides the discussion toward differentiating available frontline treatment options, focusing on the choice between dual immune checkpoint inhibitor therapy and combinations of immunotherapy with VEGF receptor targeted therapies.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6392167538112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/first-line-treatment-selection-in-advanced-renal-cell-carcinoma</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1a6d64ac5992ae4d126fd67e1a074defa42ab2d1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[First-Line Treatment Selection in Advanced Renal Cell Carcinoma ]]></video:title><video:description><![CDATA[In this opening segment on advanced renal cell carcinoma, Ornstein introduces the evolving frontline treatment landscape, highlighting the expanded role of immune checkpoint inhibitor–based combinations and VEGF receptor–targeted therapies. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6392167138112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/defining-early-relapse-and-treatment-selection-in-multiple-myeloma</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1037680179dd22031bb6c3ea404d1118f74f5c6e-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Defining Early Relapse and Treatment Selection in Multiple Myeloma ]]></video:title><video:description><![CDATA[]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391845207112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/framing-litespark-011-in-a-changing-rcc-landscape</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b7614e52fff7bdd6f4493c629c62e21f57b92a0c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Framing LITESPARK-011 in a Changing RCC Landscape]]></video:title><video:description><![CDATA[]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6392173271112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/apos-president-highlights-focus-on-expanding-access-education</loc><video:video><video:publication_date>2026-03-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1eff2b69a1450f9d01bb3a73241e94f1902f6106-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[APOS President Highlights Focus on Expanding Access, Education ]]></video:title><video:description><![CDATA[Jesse Fann, MD, MPH, spoke about what he hopes to accomplish during the 2-year term of his APOS presidency. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6392158505112 </video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/elucidating-mindfulness-impacts-on-qol-psychosocial-symptoms-in-oncology</loc><video:video><video:publication_date>2026-03-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/8a72228a04347a901c979080f586ea7c296c2c93-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Elucidating Mindfulness Impacts on QOL, Psychosocial Symptoms in Oncology]]></video:title><video:description><![CDATA[Linda E. Carlson, PhD, RPsych, asserted mindfulness programs have strong evidence in managing psychosocial symptoms, but require increasing access for use.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391752316112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/proactive-toxicity-management-and-dose-modification-in-egfr-mutated-metastatic-non-small-cell-lung-cancer</loc><video:video><video:publication_date>2026-03-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d0dca9d03ca4cc3748d1895713aba71b957f1366-850x476.png</video:thumbnail_loc><video:title><![CDATA[Proactive Toxicity Management and Dose Modification in EGFR Mutated Metastatic Non-Small Cell Lung Cancer]]></video:title><video:description><![CDATA[In this segment, the discussion centers on proactive toxicity management strategies in EGFR mutated metastatic non-small cell lung cancer. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390394749112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/subcutaneous-administration-in-egfr-mutated-metastatic-non-small-cell-lung-cancer</loc><video:video><video:publication_date>2026-03-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d0dca9d03ca4cc3748d1895713aba71b957f1366-850x476.png</video:thumbnail_loc><video:title><![CDATA[Subcutaneous Administration in EGFR Mutated Metastatic Non-Small Cell Lung Cancer]]></video:title><video:description><![CDATA[In this segment, Dr. Devarakonda asks Dr. Rous to interpret the clinical implications of the FDA approval of subcutaneous amivantamab in combination with lazertinib, including the availability of once monthly dosing. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390392606112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/strategies-for-managing-cancer-related-fatigue-impact-on-cognitive-function</loc><video:video><video:publication_date>2026-03-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/07e300064ef8eae8ed83da907da779480782a1fd-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Strategies for Managing Cancer-Related Fatigue, Impact on Cognitive Function]]></video:title><video:description><![CDATA[Yesne Alici, MD, discussed cancer-related fatigue and cognitive impairment and addressed sleep disturbances and AEs such as anemia to improve outcomes.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391737524112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/teclistamab-combo-approval-affirms-role-of-anti-bcma-therapy-in-myeloma</loc><video:video><video:publication_date>2026-03-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/76c6bb7f1e2ec9d2405a6c3d06860cda9fded3b0-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Teclistamab Combo Approval Affirms Role of Anti-BCMA Therapy in Myeloma]]></video:title><video:description><![CDATA[It is a good option to move to BCMA-directed therapy for patients with multiple myeloma after an initial relapse, said María-Victoria Mateos, MD, PhD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391560269112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/when-to-consider-a-re-biopsy-in-the-metastatic-crpc-treatment-course</loc><video:video><video:publication_date>2026-03-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/75b3b24cf9a725a682c7a13afb60e4bb6d80e9d1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[When to Consider a Rebiopsy in the Metastatic CRPC Treatment Course]]></video:title><video:description><![CDATA[PET-negative soft tissue disease may prompt a rebiopsy, particularly in enriching for treatment-emergent neuroendocrine prostate cancers.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391666123112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/neoadjuvant-strategies-and-early-biomarker-testing-in-egfr-mutated-nsclc</loc><video:video><video:publication_date>2026-03-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9e600743c27804eed73368187e7a4eac4f4d9211-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Neoadjuvant Strategies and Early Biomarker Testing in EGFR-Mutated NSCLC ]]></video:title><video:description><![CDATA[NEADORA data highlights why early NGS guides resectable EGFR lung cancer care, favoring perioperative osimertinib and avoiding checkpoint inhibitors.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391555074112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/us-registry-comparing-second-line-car-t-products-in-lbcl</loc><video:video><video:publication_date>2026-03-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/8cc39f59a281a15f46324cb54550846f2cb771e6-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[US Registry: Comparing Second-Line CAR-T Products in LBCL]]></video:title><video:description><![CDATA[Team Roswell presents ABC Consortium real-world data from 15 US centers comparing second-line outcomes with axi-cel, liso-cel, and a third CAR T product in large B-cell lymphoma, including manufacturing timelines, bridging therapy, response, survival, and key toxicities. The discussion highlights faster vein-to-vein time and fewer out-of-spec products with axi-cel, broadly similar efficacy between axi-cel and liso-cel, and higher rates of cytokine release syndrome/neurotoxicity with axi-cel alongside lower acute toxicity with liso-cel. Team NYC cross-examines the interpretation, especially the limited sample for the third product, and the panel pivots to practical post–CAR T survivorship issues like infections, hypogammaglobulinemia, IVIg use, and the need for more standardized supportive-care practices.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391196386112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/evolving-adjuvant-therapy-in-early-stage-egfr-mutated-nsclc-insights-from-adaura</loc><video:video><video:publication_date>2026-03-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9e600743c27804eed73368187e7a4eac4f4d9211-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[ Evolving Adjuvant Therapy in Early-Stage EGFR-Mutated NSCLC: Insights From ADAURA ]]></video:title><video:description><![CDATA[Experts explain how adjuvant osimertinib changes post-surgery EGFR lung cancer care, from rapid testing to real-world adherence.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391554969112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/investigating-differences-between-esophagogastric-cancers-across-age-groups</loc><video:video><video:publication_date>2026-03-24</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1355fe8063ef9313d7624f0d5d23633a4b35b1fe-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Investigating Differences Between Esophagogastric Cancers Across Age Groups]]></video:title><video:description><![CDATA[Ryan H. Moy, MD, PhD, noted that patients with early-onset esophagogastric cancer tend to have more advanced disease.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391543955112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/can-anti-inflammatory-pathway-targeting-treatment-work-in-early-onset-crc-</loc><video:video><video:publication_date>2026-03-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/132eebef32cbfb4a2038c77ad41814505cd5707f-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Can Anti-Inflammatory Pathway-Targeting Treatment Work in Early Onset CRC?]]></video:title><video:description><![CDATA[According to Yoanna S. Pumpalova, MD, both early-onset and later-onset colorectal cancers are genetically similar in terms of somatic mutations.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391454483112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/considering-venlafaxine-as-distress-treatment-in-breast-cancer</loc><video:video><video:publication_date>2026-03-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5a9f7ac6ec10646021d2f663535d904dfe36d554-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Considering Venlafaxine as Distress Treatment in Breast Cancer]]></video:title><video:description><![CDATA[Venlafaxine was found to be an effective treatment for patients with breast cancer who are experiencing vasomotor symptoms. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391459790112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/could-hematologic-markers-be-prognostic-for-survival-in-rcc-</loc><video:video><video:publication_date>2026-03-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c078a937e579408e3ca7a1480a7389cc6c7f7053-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Could Hematologic Markers Be Prognostic for Survival in RCC?]]></video:title><video:description><![CDATA[Two genitourinary oncologists discussed research examining germline platelet polygenic risk scores to predict survival outcomes in kidney cancer.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391283894112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/what-is-the-most-effective-way-to-identify-young-patients-with-colorectal-cancer-</loc><video:video><video:publication_date>2026-03-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/78401b6c76fd4a2421c665815275095a89f3f963-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[What Is the Most Effective Way to Identify Young Patients With Colorectal Cancer?]]></video:title><video:description><![CDATA[It is unlikely that guidelines recommend screening patients younger than 45 years for colorectal cancer, according to Yoanna S. Pumpalova, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391252787112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/optimizing-transplantation-outcomes-across-hematologic-oncology-populations</loc><video:video><video:publication_date>2026-03-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/8a2d3e65c51834482c64f93fe5ecc8a50cd29495-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Optimizing Transplantation Outcomes Across Hematologic Oncology Populations]]></video:title><video:description><![CDATA[Patients with high-risk or intermediate-risk disease may benefit from allogeneic stem cell transplantation as a potentially “curative approach.”]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391017990112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/impact-of-treatment-administration-on-patient-experience-in-egfr-mutated-metastatic-non-small-cell-lung-cancer</loc><video:video><video:publication_date>2026-03-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d0dca9d03ca4cc3748d1895713aba71b957f1366-850x476.png</video:thumbnail_loc><video:title><![CDATA[Impact of Treatment Administration on Patient Experience in EGFR Mutated Metastatic Non-Small Cell Lung Cancer]]></video:title><video:description><![CDATA[In this segment, Dr. Devarakonda asks Dr. Singhi to address how route of administration and treatment logistics influence clinical decision making in EGFR mutated metastatic non-small cell lung cancer.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390392794112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/practical-decision-making-in-first-line-egfr-mutated-metastatic-non-small-cell-lung-cancer</loc><video:video><video:publication_date>2026-03-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d0dca9d03ca4cc3748d1895713aba71b957f1366-850x476.png</video:thumbnail_loc><video:title><![CDATA[Practical Decision Making in First Line EGFR Mutated Metastatic Non-Small Cell Lung Cancer]]></video:title><video:description><![CDATA[In this segment, Dr. Devarakonda asks Dr. Rotow to move beyond clinical trial data and discuss the real world factors that influence first line treatment selection in EGFR mutated metastatic non-small cell lung cancer. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390394644112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/liquid-biopsies-blood-based-mced-tests-for-detecting-crc-in-young-patients</loc><video:video><video:publication_date>2026-03-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/13e7e119716b43abea6a0bfa989f9082b01b91f8-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Liquid Biopsies, Blood-Based MCED Tests for Detecting CRC in Young Patients]]></video:title><video:description><![CDATA[The NHS-Galleri study findings showed that multicancer screening with the Galleri test did not reduce the number of cancers found at stage III or IV.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391184346112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/highlighting-en-bloc-resection-in-bladder-cancer-surgery</loc><video:video><video:publication_date>2026-03-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5992ee98a42dabdea0b3752ade01cf1bdfb2cf0f-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Highlighting En-Bloc Resection in Bladder Cancer Surgery]]></video:title><video:description><![CDATA[The addition of Bacillus Calmette-Guérin to ERBT significantly reduced 1-year recurrence rates among patients with high-risk, muscle-invasive disease.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391140616112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/why-cognitive-behavioral-therapy-for-insomnia-remains-the-gold-standard-in-oncology</loc><video:video><video:publication_date>2026-03-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/2974f29b57a29827d942ae095520e07fde9c53d3-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Why Cognitive Behavioral Therapy for Insomnia Remains the Gold Standard in Oncology]]></video:title><video:description><![CDATA[Ben Brewer, PsyD, discussed the 5 core components of cognitive behavioral therapy for insomnia.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391176221112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/determining-transplantation-needs-and-risk-factors-in-myelofibrosis-care</loc><video:video><video:publication_date>2026-03-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ca708e09a67e0a63bf0d3bc126f43d73a4a4c979-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Determining Transplantation Needs and Risk Factors in Myelofibrosis Care]]></video:title><video:description><![CDATA[Donor availability may influence the treatment decision-making process regarding the use of transplantation for those with myelofibrosis.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391087810112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/real-world-car-t-comparisons-axi-cel-vs-liso-cel-in-2l-lbcl</loc><video:video><video:publication_date>2026-03-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/8cc39f59a281a15f46324cb54550846f2cb771e6-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Real-World CAR-T Comparisons: Axi-cel vs Liso-cel in 2L LBCL]]></video:title><video:description><![CDATA[Team Roswell presents ABC Consortium real-world data from 15 US centers comparing second-line outcomes with axi-cel, liso-cel, and a third CAR T product in large B-cell lymphoma, including manufacturing timelines, bridging therapy, response, survival, and key toxicities. The discussion highlights faster vein-to-vein time and fewer out-of-spec products with axi-cel, broadly similar efficacy between axi-cel and liso-cel, and higher rates of cytokine release syndrome/neurotoxicity with axi-cel alongside lower acute toxicity with liso-cel. Team NYC cross-examines the interpretation, especially the limited sample for the third product, and the panel pivots to practical post–CAR T survivorship issues like infections, hypogammaglobulinemia, IVIg use, and the need for more standardized supportive-care practices.

]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390644544112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/integrating-mental-health-screenings-into-early-routine-cancer-care</loc><video:video><video:publication_date>2026-03-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/809a6670e1138429b0e14c88d2a0ded72298b061-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Integrating Mental Health Screenings Into Early Routine Cancer Care]]></video:title><video:description><![CDATA[Julian Hong, MD, MS, stated that the demand for highly specialized teams trained to combat the onset of mental health disorders outpaces the supply.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391074158112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/which-novel-drug-classes-hold-promise-in-multiple-myeloma-therapy-</loc><video:video><video:publication_date>2026-03-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f835d6e619493f93fe4cd9bfb36a4071614119f5-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Which Novel Drug Classes Hold Promise in Multiple Myeloma Therapy?]]></video:title><video:description><![CDATA[FcRH5 is emerging as a potentially highly active target for cellular therapies in multiple myeloma care, said Natalia Neparidze, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391028056112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/how-do-mental-health-disorders-impact-all-cause-cancer-mortality-</loc><video:video><video:publication_date>2026-03-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d9c83e12b60cc2bf9eb1ca2caeee3d4fd9a6a9b5-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[How Do Mental Health Disorders Impact All-Cause Cancer Mortality?]]></video:title><video:description><![CDATA[According to a study published in Cancer, new-onset mental health disorders increased the risk of all-cause mortality in patients with cancer.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391075999112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/staying-up-to-date-on-the-latest-advancements-across-hematologic-oncology</loc><video:video><video:publication_date>2026-03-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e5a692a2eb9576b88a69038d59c1b39290c28d10-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Staying Up to Date on the Latest Advancements Across Hematologic Oncology]]></video:title><video:description><![CDATA[Adverse effects of novel immunotherapies appear controllable compared with chemotherapy in hematologic malignancies, according to Guenther Koehne, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391017900112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/determining-suitable-therapeutic-strategies-across-various-cll-populations</loc><video:video><video:publication_date>2026-03-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d6e5b28dc7bb5eb93d0b7cd5fa2be7ad1e979aa2-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Determining Suitable Therapeutic Strategies Across Various CLL Populations]]></video:title><video:description><![CDATA[Newer generations of BTK inhibitors may have fewer cardiac toxicities compared with earlier iterations, according to Nicole Lamanna, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390794093112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/the-impact-of-glp-1-mediated-weight-loss-on-mammographic-density-and-radiomic-risk</loc><video:video><video:publication_date>2026-03-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/30089ea313ce489d6076ead7336002569a900e7f-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[The Impact of GLP-1–Mediated Weight Loss on Mammographic Density and Radiomic Risk]]></video:title><video:description><![CDATA[Julia E. McGuiness, MD, discussed the timeline for mammographic density changes following significant weight loss.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390865076112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/redefining-mhspc-sequencing-exploring-impact-of-psmaddition</loc><video:video><video:publication_date>2026-03-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a571702aa2a2088b1cfbc51ea965493ba327f3e9-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Redefining mHSPC Sequencing: Exploring Impact of PSMAddition]]></video:title><video:description><![CDATA[Scott Tagawa, MD, MS, FACP, FASCO, evaluated how the rPFS improvement with lutetium 177 could help integrate the treatment into the frontline metastatic HSPC setting.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390886733112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/rusfertide-may-become-part-of-polycythemia-vera-armamentarium</loc><video:video><video:publication_date>2026-03-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/db77d42a2bcaf31e0cc9bad1039d6f6a73b6ab02-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Rusfertide May Become Part of Polycythemia Vera Armamentarium]]></video:title><video:description><![CDATA[Treatment with rusfertide appears to reliably control hematocrit among those with polycythemia vera, according to Andrew Kuykendall, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390877449112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/managing-psma-pet-positive-oligometastatic-prostate-cancer</loc><video:video><video:publication_date>2026-03-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/49284023740820edf951725b6784b9a819f30f1c-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Managing PSMA-PET–Positive Oligometastatic Prostate Cancer]]></video:title><video:description><![CDATA[Oliver Sartor, MD highlighted SBRT, hormonal therapy, and the PSMA-DC regimen for patients with biochemical recurrence and PSMA-PET–positive disease.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390878183112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/stem-cell-boost-mixed-chimerism-dli-high-stakes-post-transplant-choices</loc><video:video><video:publication_date>2026-03-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f895919ad5256b6ae145519f38dc3232410c2c36-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Stem Cell Boost, Mixed Chimerism & DLI: High-Stakes Post-Transplant Choices]]></video:title><video:description><![CDATA[Yan Leyfman, MD, discussed the factors that may ultimately define the next era of transplant medicine across hematologic malignancies.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390858809112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/examining-discontinuation-outcomes-of-ev-in-metastatic-urothelial-carcinoma</loc><video:video><video:publication_date>2026-03-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7a85fa7f0810441a40b4962577593e2594560a26-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Examining Discontinuation Outcomes of EV in Metastatic Urothelial Carcinoma]]></video:title><video:description><![CDATA[Among patients who discontinued enfortumab vedotin due to an ongoing response or toxicity, 57% were treatment-free and alive 1 year later.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390748866112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/selecting-combination-versus-monotherapy-in-egfr-mutated-metastatic-non-small-cell-lung-cancer</loc><video:video><video:publication_date>2026-03-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d0dca9d03ca4cc3748d1895713aba71b957f1366-850x476.png</video:thumbnail_loc><video:title><![CDATA[Selecting Combination Versus Monotherapy in EGFR Mutated Metastatic Non-Small Cell Lung Cancer]]></video:title><video:description><![CDATA[In this segment, Dr. Devarakonda asks Dr. Rotow to outline the advantages and limitations of combination regimens compared with single agent EGFR tyrosine kinase inhibitors in the first line treatment of EGFR mutated metastatic non-small cell lung cancer. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390392707112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/relapsed-dlbcl-navigating-car-t-logistics-work-and-caregiving</loc><video:video><video:publication_date>2026-03-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/22008ccfe38d91e439dc2bf7df618ed7030ced07-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Relapsed DLBCL: Navigating CAR-T Logistics, Work, and Caregiving]]></video:title><video:description><![CDATA[Panelists review a patient with DLBCL relapsing 8 months after frontline Pola-R-CHP following an initial complete response. With low symptom burden and favorable performance status, the debate centers on optimal second-line strategy, outpatient CAR T feasibility, caregiver limitations, and balancing treatment intensity with quality-of-life and employment considerations in an urban setting.

]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389181428112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/guideline-evolution-and-real-world-decision-making-in-egfr-mutated-metastatic-non-small-cell-lung-cancer</loc><video:video><video:publication_date>2026-03-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d0dca9d03ca4cc3748d1895713aba71b957f1366-850x476.png</video:thumbnail_loc><video:title><![CDATA[Guideline Evolution and Real World Decision Making in EGFR Mutated Metastatic Non-Small Cell Lung Cancer]]></video:title><video:description><![CDATA[In this segment, Dr. Devarakonda invites the panel to reflect on how updated clinical guidelines are shaping first line treatment patterns in EGFR mutated metastatic non-small cell lung cancer. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390394254112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/acalabrutinib-approval-offers-time-limited-approach-in-cll-sll</loc><video:video><video:publication_date>2026-03-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1fc6332485333786060116d01c1f14c6df44629c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Acalabrutinib Approval Offers Time-Limited Approach in CLL/SLL]]></video:title><video:description><![CDATA[Acalabrutinib/venetoclax may offer less toxicity compared with other therapies in chronic lymphocytic leukemia, said Nicole Lamanna, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390792727112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/car-t-decision-making-in-a-case-of-primary-refractory-dlbcl</loc><video:video><video:publication_date>2026-03-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/22008ccfe38d91e439dc2bf7df618ed7030ced07-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[CAR-T Decision Making in A Case of Primary Refractory DLBCL]]></video:title><video:description><![CDATA[Faculty analyze a primary refractory, high-intermediate–risk DLBCL case with persistent PET-positive disease after frontline R-CHOP and symptomatic progression. Discussion focuses referral for second-line CAR T and how rural geography and distance from a CAR-T center influence logistics. Panelists weigh aggressive disease biology against access barriers and caregiver availability in determining next steps.
]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389181143112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/sympathetic-signaling-and-inflammatory-caf-phenotypes-in-pancreatic-tumor-cells</loc><video:video><video:publication_date>2026-03-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/30c83d3e45c7daff23a5b1bd8ffa6e9f965167f7-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Sympathetic Signaling and Inflammatory CAF Phenotypes in Pancreatic Tumor Cells]]></video:title><video:description><![CDATA[According to Sebnem Ece Eksi, PhD, sympathetic signals led to shifts in cancer-associated fibroblasts to a more inflammatory state.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390736934112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/sympathetic-nerves-signal-to-cafs-and-promote-pancreatic-tumor-aggression</loc><video:video><video:publication_date>2026-03-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6e06cdfd81bf8e7b4655159c619826bcc0dd6a45-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Sympathetic Nerves Signal to CAFs and Promote Pancreatic Tumor Aggression]]></video:title><video:description><![CDATA[Findings from a study published by Sebnem Ece Eksi, PhD, and coauthors found that sympathetic nerves affect cancer-associated fibroblasts in a way that remodels the tissue environment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390734800112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/treatment-selection-in-biologically-aggressive-dlbcl</loc><video:video><video:publication_date>2026-03-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/8cc39f59a281a15f46324cb54550846f2cb771e6-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Treatment Selection in Biologically Aggressive DLBCL]]></video:title><video:description><![CDATA[Teams from Roswell Park and New York City discuss advances in CAR T-cell therapy for large B-cell lymphoma. Team Roswell presents real-world data comparing second-line CAR T therapy with standard salvage chemotherapy and transplant approaches, highlighting improved event-free and overall survival outcomes with CAR T. Team NYC challenges the findings, raising questions about patient selection, treatment bias, and how real-world data should be interpreted alongside randomized clinical trial results.
]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6391195515112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/advancing-knowledge-of-disease-biology-to-optimize-lung-cancer-treatment</loc><video:video><video:publication_date>2026-03-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0c204c9e5c88cae949f796f9f1afdbf0970b2a59-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Advancing Knowledge of Disease Biology to Optimize Lung Cancer Treatment]]></video:title><video:description><![CDATA[Brian Henick, MD, discussed plans to investigate agents targeting ULBP2/5/6, antibody-drug conjugates, and other novel therapies in lung cancer research.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390692553112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/dismantling-barriers-to-early-adoption-of-bispecifics-in-multiple-myeloma</loc><video:video><video:publication_date>2026-03-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/690fa9dc7ffc07cfdc0666e5e8d282ada544733d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Dismantling Barriers to Early Adoption of Bispecifics in Multiple Myeloma]]></video:title><video:description><![CDATA[Education, REMS certification, and long-term management are key barriers to the widespread adoption of bispecific antibodies in the community setting.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390630113112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/a-22-year-old-patient-with-colorectal-cancer-the-nuances-of-care</loc><video:video><video:publication_date>2026-03-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bb8328dd3c35b282bfb5b254354e8f2a78ccd53e-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[A 22-Year-Old Patient With Colorectal Cancer: The Nuances of Care]]></video:title><video:description><![CDATA[Marc Lehrer Greenwald, MD, discussed a recent patient case he had with a 22-year-old woman who was diagnosed with colorectal cancer. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390500875112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/why-is-the-incidence-of-colorectal-cancer-rising-in-young-patients-</loc><video:video><video:publication_date>2026-03-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1988c0e4aa9ee4e9ac81f453f5d574dae774975f-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Why Is the Incidence of Colorectal Cancer Rising in Young Patients?]]></video:title><video:description><![CDATA[The rising incidence of colorectal cancer among younger populations may be due to environmental factors, according to Marc Greenwald, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390501856112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/debate-round-3-car-t-vs-bispecifics-in-r-r-lbcl</loc><video:video><video:publication_date>2026-03-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/22008ccfe38d91e439dc2bf7df618ed7030ced07-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Debate Round 3: CAR-T vs Bispecifics in R/R LBCL]]></video:title><video:description><![CDATA[Panelists debate whether the treatment paradigm in relapsed/refractory LBCL has fundamentally shifted from salvage chemotherapy and autologous transplant toward novel immune-based strategies. The discussion centers on CAR T-cell therapy versus bispecific antibodies, examining differences in outcomes. Faculty explore how emerging data, sequencing considerations, and real-world constraints are redefining treatment decision-making.
]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389181427112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/interpreting-overall-survival-and-cns-outcomes-in-egfr-mutated-metastatic-non-small-cell-lung-cancer</loc><video:video><video:publication_date>2026-03-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d0dca9d03ca4cc3748d1895713aba71b957f1366-850x476.png</video:thumbnail_loc><video:title><![CDATA[Interpreting Overall Survival and CNS Outcomes in EGFR Mutated Metastatic Non-Small Cell Lung Cancer ]]></video:title><video:description><![CDATA[Experts weigh EGFR lung cancer combo therapies, cautioning against cross-trial comparisons and prioritizing CNS efficacy for brain metastases.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390394253112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/debate-round-2-car-t-decision-in-rapidly-progressing-lbcl</loc><video:video><video:publication_date>2026-03-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/22008ccfe38d91e439dc2bf7df618ed7030ced07-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Debate Round 2: CAR T Decision in Rapidly Progressing LBCL ]]></video:title><video:description><![CDATA[Panelists debate how to select between axicabtagene ciloleucel and lisocabtagene maraleucel for patients with rapidly progressive second-line DLBCL. Key arguments examine differences in efficacy signals, vein-to-vein time, and toxicity profiles and how these factors influence urgency of treatment. Faculty explore how real-world experience, institutional infrastructure, and patient-specific risk factors and lifestyle shape optimal CAR T product selection.
]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389179783112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/evolving-first-line-treatment-goals-in-egfr-mutated-metastatic-non-small-cell-lung-cancer</loc><video:video><video:publication_date>2026-03-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d0dca9d03ca4cc3748d1895713aba71b957f1366-850x476.png</video:thumbnail_loc><video:title><![CDATA[Evolving First Line Treatment Goals in EGFR Mutated Metastatic Non-Small Cell Lung Cancer]]></video:title><video:description><![CDATA[Experts unpack new EGFR-mutant lung cancer first-line options, weighing survival, CNS control, and toxicity as combo regimens reshape practice.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390394442112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/post-ash-update-real-world-evidence-informing-car-t-vs-bispecific-sequencing-in-rrmm</loc><video:video><video:publication_date>2026-03-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1188691f022c1e3c3de6a07849ab68dd6cbddcee-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Post-ASH Update: Real-World Evidence Informing CAR T vs Bispecific Sequencing in RRMM]]></video:title><video:description><![CDATA[Dr. Krina Patel reviews a real-world comparative analysis showing improved progression-free and overall survival with idecabtagene vicleucel versus teclistamab in triple-class–exposed relapsed or refractory multiple myeloma, and discusses its implications for treatment sequencing and individualized care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390383864112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/trifluridine-tipiracil-associated-neutropenia-associated-with-improved-outcomes-in-mcrc</loc><video:video><video:publication_date>2026-03-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5a8774726c03bb9437cbf89e5fa9cd98fb16eddb-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Trifluridine/Tipiracil-Associated Neutropenia Associated With Improved Outcomes in mCRC]]></video:title><video:description><![CDATA[According to Marwan G. Fakih, MD, neutropenia may be a biomarker of benefit for patients with metastatic colorectal cancer receiving trifluridine/tipiracil and bevacizumab.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390382320112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/comparable-ipilimumab-nivolumab-outcomes-observed-in-older-rcc-population</loc><video:video><video:publication_date>2026-03-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b1ab69199f73730cd0765e9f5b1bc0a8fd4306be-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Comparable Ipilimumab/Nivolumab Outcomes Observed in Older RCC Population]]></video:title><video:description><![CDATA[Although older patients saw a greater rate of AE-related discontinuations, survival outcomes were similar between groups.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390392741112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/new-zenocutuzumab-findings-provide-hope-for-targeting-rare-nsclc-subtypes</loc><video:video><video:publication_date>2026-03-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/990cefb10db60f64248ec10d652672d310f7cbf9-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[New Zenocutuzumab Findings Provide Hope for Targeting Rare NSCLC Subtypes]]></video:title><video:description><![CDATA[An updated analysis of the eNRGy trial showed that zenocutuzumab may provide meaningful benefit beyond initial disease progression.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390327652112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/what-should-patients-with-mcrc-consider-when-deciding-treatment-options-</loc><video:video><video:publication_date>2026-03-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/8cd924319889aa4173d8de33608dd1485f142769-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[What Should Patients With mCRC Consider When Deciding Treatment Options?]]></video:title><video:description><![CDATA[Patients with metastatic colorectal cancer who desire better disease control are best served with trifluridine/tipiracil plus bevacizumab, according to Marwan G. Fakih, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390384638112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/sequencing-strategies-and-safety-priorities-for-high-risk-bispecific-exposed-patients-preparing-for-car-t-cell-therapy</loc><video:video><video:publication_date>2026-03-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ad7959e1c8e63f58cbaebaeb09376c0bc2500a5a-866x486.png</video:thumbnail_loc><video:title><![CDATA[Sequencing Strategies and Safety Priorities for High Risk, Bispecific Exposed Patients Preparing for CAR T-Cell Therapy ]]></video:title><video:description><![CDATA[Panelists discuss how high-risk disease biology and recent bispecific therapy heighten the need for timely, individualized sequencing and rigorous safety planning around infections, cytopenias, and early monitoring. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6386250520112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/evaluating-car-t-cell-suitability-and-pre-treatment-planning-after-bispecific-exposure-in-high-risk-multiple-myeloma</loc><video:video><video:publication_date>2026-03-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ad7959e1c8e63f58cbaebaeb09376c0bc2500a5a-866x486.png</video:thumbnail_loc><video:title><![CDATA[Evaluating CAR T-Cell Suitability and Pre Treatment Planning After Bispecific Exposure in High Risk Multiple Myeloma ]]></video:title><video:description><![CDATA[Panelists discuss how recent bispecific exposure does not necessarily preclude CAR T, but timing, disease tempo, infection/immune assessments, and realistic scheduling expectations shape readiness and planning. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6386249744112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/prioritizing-early-detection-to-improve-survival-outcomes-in-pancreatic-cancer</loc><video:video><video:publication_date>2026-03-02</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/2e29e30adedfde67210d96ea426bdbd2264c5d22-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Prioritizing Early Detection to Improve Survival Outcomes in Pancreatic Cancer]]></video:title><video:description><![CDATA[Diane Simeone, MD, explained that shifting diagnosis toward earlier stages could raise the pancreatic cancer survival rate from 13% to over 80% for certain patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390272768112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/sustained-ctdna-negativity-confers-optimal-outcomes-in-mibc</loc><video:video><video:publication_date>2026-03-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/268263322127cee2c2a5b6ca5c820e84e3893fc1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Sustained ctDNA Negativity Confers Optimal Outcomes in MIBC]]></video:title><video:description><![CDATA[The majority of patients experiencing recurrence of their MIBC within 6 months of study start had high concentrations of ctDNA at baseline.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390164903112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/how-do-the-resources-available-to-patients-with-cancer-differ-by-treatment-settings-</loc><video:video><video:publication_date>2026-03-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/61ac4d8858ef9817e1ad06c202027371ed1d785d-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[How do the Resources Available to Patients With Cancer Differ by Treatment Settings?]]></video:title><video:description><![CDATA[Several differences arise between community oncology centers and institutional oncology centers regarding the tools available and requirements of patients with cancer.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390073587112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/potential-iberdomide-approval-may-offer-another-choice-in-multiple-myeloma</loc><video:video><video:publication_date>2026-03-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/07fc0b610816dd467e4894332b06873bc734eda1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Potential Iberdomide Approval May Offer Another Choice in Multiple Myeloma]]></video:title><video:description><![CDATA[An effective regimen that partly incorporates oral therapy may be favorable from a patient convenience perspective, said Sagar Lonial, MD, FACP, FASCO.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389998144112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/how-can-novel-immunotherapies-bolster-radiotherapy-in-prostate-cancer-</loc><video:video><video:publication_date>2026-02-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7e71d98f5073b0339ab55aac9170bfce5cd7772c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[How Can Novel Immunotherapies Bolster Radiotherapy in Prostate Cancer? ]]></video:title><video:description><![CDATA[CAR T-cell therapies and T-cell engagers may produce an “exciting” benefit on the radiosensitization of prostate tumors.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390158864112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/examining-pembrolizumab-combo-safety-in-high-risk-prostate-cancer</loc><video:video><video:publication_date>2026-02-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/52586399a1bfa4f7252ed001a1dab7f3438980db-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Examining Pembrolizumab Combo Safety in High-Risk Prostate Cancer]]></video:title><video:description><![CDATA[The phase 2 study aimed to compare the safety of pembrolizumab and radiation with or without olaparib in this high-risk population.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390101700112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/data-show-comparable-immunotherapy-outcomes-across-rcc-age-populations</loc><video:video><video:publication_date>2026-02-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/22f6191f7c38fd506eaf27f6ca802a4909d6f310-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Data Show Comparable Immunotherapy Outcomes Across RCC Age Populations]]></video:title><video:description><![CDATA[Despite differences in treatment tolerance across different RCC subgroups, survival outcomes were similar in a retrospective study.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390075497112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/lessons-from-the-withdrawal-of-atezolizumab-in-metastatic-tnbc</loc><video:video><video:publication_date>2026-02-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f2b8259a6acbad00174e944108e4a0e496959077-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Lessons From the Withdrawal of Atezolizumab in Metastatic TNBC]]></video:title><video:description><![CDATA[Sarah Poland, MD, discussed the divergence between the IMpassion130 and IMpassion131 trials and the critical role of confirmatory trials in oncology.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390073497112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/overcoming-challenges-to-access-for-proton-based-radiotherapy-in-opscc</loc><video:video><video:publication_date>2026-02-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1919dfb282a79cba8d41486bf59a2a241447fecb-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Overcoming Challenges to Access for Proton-Based Radiotherapy in OPSCC]]></video:title><video:description><![CDATA[The expansion of clinical trials evaluating proton-based radiotherapy could elucidate its benefits and increase its access across the US.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389892274112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/mds-mpn-correlates-with-worse-allogeneic-transplantation-outcomes</loc><video:video><video:publication_date>2026-02-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/fc5bf6b34d30f9583d9a4fab77bfcb1a2856e859-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[MDS/MPN Correlates With Worse Allogeneic Transplantation Outcomes]]></video:title><video:description><![CDATA[Retrospective data show that relapse-free survival outcomes were worse for patients with MDS/MPN compared with those who had other types of MDS.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390070044112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/the-complexity-of-insurance-for-patients-with-cancer-in-community-settings</loc><video:video><video:publication_date>2026-02-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/2fcfa6e374c08001dbd516791354f972f42b8e26-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[The Complexity of Insurance for Patients with Cancer in Community Settings]]></video:title><video:description><![CDATA[Often, patients in middle-income settings, are the patients who are impacted most by insurance deductibles, according to Loretta Nastoupil, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6390073207112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/debate-round-1-treatment-selection-in-biologically-aggressive-dlbcl</loc><video:video><video:publication_date>2026-02-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/22008ccfe38d91e439dc2bf7df618ed7030ced07-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Debate Round 1: Treatment selection in biologically aggressive DLBCL]]></video:title><video:description><![CDATA[Panelists debate whether high-risk disease biology should accelerate referral for CAR T-cell therapy in second-line DLBCL. Key arguments consider patient-specific sequencing approaches, emphasizing individualized assessments before committing to CAR T. The opposing argument supports early referral for CAR T in biologically high-risk  patients. Faculty weigh the balance between urgency and personalization, exploring how disease kinetics, logistical barriers, and real-world practice patterns influence optimal timing of referral.
]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389179197112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/managing-toxicity-expectations-and-sequencing-considerations-for-car-t-cell-therapy-in-multiple-myeloma</loc><video:video><video:publication_date>2026-02-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ad7959e1c8e63f58cbaebaeb09376c0bc2500a5a-866x486.png</video:thumbnail_loc><video:title><![CDATA[Managing Toxicity Expectations and Sequencing Considerations for CAR T-Cell Therapy in Multiple Myeloma]]></video:title><video:description><![CDATA[Panelists discuss how clinicians set expectations for the acute toxicity window and monitoring while also considering how rising disease burden or prior BCMA exposure can influence efficacy and reinforce urgency of referral. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6386248880112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/us-real-world-car-t-patterns-in-r-r-lbcl-ash-2025-updates-from-abc-consortium-</loc><video:video><video:publication_date>2026-02-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/22008ccfe38d91e439dc2bf7df618ed7030ced07-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[US Real World CAR-T Patterns in R/R LBCL (ASH 2025 Updates from ABC Consortium)]]></video:title><video:description><![CDATA[Panelists discuss real-world data from the US ABC Consortium evaluating axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel in relapsed/refractory LBCL. Faculty discuss key differences in manufacturing, review outcomes, and consider toxicity profiles for each of the CAR T products in clinical practice.
]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389181334112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/assessing-car-t-cell-eligibility-and-early-referral-decisions-in-relapsed-multiple-myeloma</loc><video:video><video:publication_date>2026-02-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ad7959e1c8e63f58cbaebaeb09376c0bc2500a5a-866x486.png</video:thumbnail_loc><video:title><![CDATA[Assessing CAR T-Cell Eligibility and Early Referral Decisions in Relapsed Multiple Myeloma ]]></video:title><video:description><![CDATA[Panelists discuss how older patients with cardiac/renal comorbidities may still be appropriate CAR T candidates when conditions are well-managed, and why early evaluation protects eligibility and aligns care with patient goals. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6386250035112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/beyond-crs-redefining-car-t-toxicity-in-2026</loc><video:video><video:publication_date>2026-02-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b62061e6d52503cb13ed867a40cc45d6a9239d6e-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Beyond CRS: Redefining CAR T-Cell Toxicity in 2026]]></video:title><video:description><![CDATA[Yan Leyfman, MD, reviewed how toxicity management in hematologic oncology is shifting to phenotype- and mechanism-informed intervention.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389972244112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/how-has-immunotherapy-evolved-in-breast-cancer-treatment-</loc><video:video><video:publication_date>2026-02-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1f9ad51555cfecaac72e0ab2bc48de4431f2947c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[How Has Immunotherapy Evolved in Breast Cancer Treatment?]]></video:title><video:description><![CDATA[Sarah Poland, MD, discussed the transition of breast cancer from an "immunologically cold" tumor to a target for checkpoint inhibitors, highlighting the pivotal role of the KEYNOTE-012 trial.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389884273112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/comparing-outcomes-in-aya-vs-older-populations-receiving-liso-cel-for-lbcl</loc><video:video><video:publication_date>2026-02-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5c7b829c0bbd94a4b92a40c39d7d862680fbe406-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Comparing Outcomes in AYA Vs Older Populations Receiving Liso-cel for LBCL]]></video:title><video:description><![CDATA[Irtiza Sheikh, DO, sought to assess the impact of age and clinical setting on liso-cel efficacy in patients with large B-cell lymphoma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389822522112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/the-intricacies-of-the-willingness-to-pay-threshold-in-cancer-care</loc><video:video><video:publication_date>2026-02-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/2cfd382cfafe3a18ee8d6468c101cd5f13812370-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[The Intricacies of The Willingness-To-Pay Threshold in Cancer Care]]></video:title><video:description><![CDATA[The willingness-to-pay metric is a tool that varies by individual country, which is used to determine how much a patient might pay for their treatment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389817324112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/novel-small-molecule-shows-early-activity-in-pretreated-multiple-myeloma</loc><video:video><video:publication_date>2026-02-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ca541bef6079c97d2e9d3ece034603e78b223809-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma]]></video:title><video:description><![CDATA[Hematologic adverse effects with KTX-1001 among patients with relapsed/refractory multiple myeloma were “very well expected” in a phase 1 trial.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389799274112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/characterizing-tils-in-pancreatic-net-liver-metastases</loc><video:video><video:publication_date>2026-02-24</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c6791a135e2df2ac9c52f67e6d9078194214e7cd-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Characterizing TILs in Pancreatic NET Liver Metastases]]></video:title><video:description><![CDATA[Based on the ability for select TILs to confer antitumor activity, Mauro Cives, MD, began his research assessing TCR-based therapies in pancreatic NETs.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389764955112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/evaluating-the-cost-effectiveness-of-immunotherapy-in-lung-cancers</loc><video:video><video:publication_date>2026-02-24</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/32a7e561dbeafc24c8ac0c8758bb7a2f86412b1c-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Evaluating the Cost-Effectiveness of Immunotherapy in Lung Cancers]]></video:title><video:description><![CDATA[Though durvalumab was priced higher than most willingness-to-pay thresholds, an initiative out of Singapore demonstrated that difference can be managed.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389802302112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/orca-t-shows-reassuring-outcomes-across-hematologic-malignancies</loc><video:video><video:publication_date>2026-02-24</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c707766d5d1bfd775c51281dbebc6fd361325659-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Orca-T Shows “Reassuring” Outcomes Across Hematologic Malignancies]]></video:title><video:description><![CDATA[Data from the phase 3 Precision-T trial show improvements in overall survival and relapse-free survival with the use of Orca-T.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389639350112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/first-in-world-leukemia-trial-aims-to-leave-no-patients-behind</loc><video:video><video:publication_date>2026-02-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/34bd4844b9d45e4a3520b032e1baaeda2b1a8bcf-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[First-in-World Leukemia Trial Aims to Leave No Patients Behind]]></video:title><video:description><![CDATA[A phase 2 trial in mixed phenotype acute leukemia shows that “big things” can happen regardless of where patients live or the rarity of their diseases.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389635919112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/coordinating-multidisciplinary-radiation-oncology-in-cns-cancers</loc><video:video><video:publication_date>2026-02-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9b4d90e8a7effb6ac72165103c6c43371ed0b88b-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Coordinating Multidisciplinary Radiation Oncology in CNS Cancers]]></video:title><video:description><![CDATA[According to Charlotte Rivers, MD, it’s important for patients with CNS cancers to meet with all involved doctors so they can make an informed decision regarding their care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389580971112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/balancing-local-control-with-long-term-cosmesis-in-re-irradiation</loc><video:video><video:publication_date>2026-02-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b87b73802cf5278256eae3134c4d9754adc7d4cd-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Balancing Local Control With Long-Term Cosmesis in Re-Irradiation]]></video:title><video:description><![CDATA[J. Isabelle Choi, MD, shared her specific fractionation preferences and prophylactic strategies to combat adverse effects associated with radiation.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389635379112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/car-t-2-0-expanding-access-speed-and-precision</loc><video:video><video:publication_date>2026-02-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5bff360c9c1525b38540056e6398797d13e8068d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[CAR T 2.0: Expanding Access, Speed, and Precision]]></video:title><video:description><![CDATA[Yan Leyfman, MD, shared key clinical and practice-shaping insights related to cellular therapy from the 2026 Tandem Meetings.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389585599112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/redefining-frontline-therapy-in-undifferentiated-pleomorphic-sarcoma</loc><video:video><video:publication_date>2026-02-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/163e5401bf443d9c86db496f7eb3192cc5629d2b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Redefining Frontline Therapy in Undifferentiated Pleomorphic Sarcoma]]></video:title><video:description><![CDATA[Seth M. Pollack, MD, discussed how the ECOG-ACRIN EA7222 trial could establish doxorubicin/pembrolizumab as the new frontline standard for undifferentiated pleomorphic sarcoma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389632031112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/spotlighting-the-netrf-supporting-research-in-an-understudied-field</loc><video:video><video:publication_date>2026-02-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c5a4cdfe33476679383b81772a3e392b81eaa4f7-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Spotlighting the NETRF: Supporting Research in an Understudied Field]]></video:title><video:description><![CDATA[Suzann Duan, PhD, anticipates the release of a paper she coauthored exploring the role of Hedgehog signaling in NETs, as well as within the aging landscape.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6389581156112</video:player_loc></video:video></url></urlset>